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Changes in Circulating Metabolites During Weight Loss are
Associated with Adiposity Improvement, and Body Weight
and Adiposity Regain During Weight Loss Maintenance: The
SATIN Study
Christopher Papandreou, Jesús García-Gavilán, Lucía Camacho-Barcia, Thea Toft Hansen,
Joanne A. Harrold, Anders Sjödin, Jason C. G. Halford, and Mònica Bulló*
Scope: To examine the relationship between changes in circulating
metabolites during diet-induced weight loss and changes of adiposity. This
study also investigates changes in these metabolites in relation to body
weight and adiposity regain during a weight loss maintenance period.
Methods and Results: This cohort study is nested within the Satiety
Innovation (SATIN) study. Participants (n = 162) achieving ≥8% weight loss
during an initial 8-week low-calorie formula diet (LCD) are included in a
12-week weight loss maintenance period. A targeted metabolite profiling
(123 metabolites) approach is applied using three different platforms (proton
nuclear magnetic resonance, liquid chromatography mass spectrometry, gas
chromatography mass spectrometry). Changes in several lipid species and
citric acid are significantly associated with greater reduction of body weight,
total fat, and abdominal adiposity distribution during the LCD. Decreases in
the concentrations of lysophosphatidylcholines (LPCs) 14:0, LPC 20:3,
phosphatidylcholine (PC) 32:2, PC 38:3, sphingomyelin (SM) 32:2, and
increases in citric acid concentrations during the LCD are associated with
adiposity regain and loss, respectively, during the weight loss maintenance
period.
Conclusions: The results show that weight loss is associated with changes in
lipid species and citric acid. These changes are related to subsequent weight
and adiposity regain identifying the adipose lipid metabolism as an important
factor for the maintenance of lost weight and adiposity.
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Overweight and obesity are amongst
the biggest health concerns world-
wide as they are major risk factors for
other highly prevalent chronic health
conditions, including cardiometabolic
diseases,[1] and several types of cancer.[2]
Prevention and treatment of overweight
and obesity are therefore critical is-
sues from a public health perspective.
Both weight loss and weight regain
prevention have great health impact.
Of these, it is widely accepted that the
main challenge for obesity treatment is
weight loss maintenance. Several studies
indicate that a healthy weight loss of
5–10% can be achieved regardless of
which behavioral or pharmacological
treatments are employed,[3] but weight
is gradually regained in the vast majority
of individuals.[4,5] Yet, strategies and
physiological mechanisms supporting
the maintenance of an achieved weight
loss are less well explored.
Weight loss maintenance is hindered
by a complex interaction of environ-
mental, biological, behavioral, and
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cognitive factors, which are only partly known.[6] Difficulties
in maintaining weight loss may stem from the metabolic and
physiologic responses resisting the maintenance of decreased
body weight.[7–10] Metabolomics, through a systematic evalu-
ation of small-molecule metabolites in biological fluids, may
help to identify these metabolic alterations. Although vari-
ous low-calorie weight loss diets are effective for the treat-
ment of obesity and the improvement of body composition
and fat distribution,[11] little is known about how metabolic
responses during weight loss are associated with changes of
adiposity,[12,13] body composition,[13] and fat distribution.[13] Fur-
thermore, whether changes in metabolomic profiles elicited by
weight loss and associated with adiposity changes could be as-
sociated with successful maintenance weight loss and adiposity
reductions remains unknown.
Therefore, we examined the relationship between changes in
circulating metabolites during a dietary intervention inducing
weight loss (≥8% of initial body weight) and adiposity reduction.
We also investigated whether changes in these metabolites were
associated with weight and adiposity regain during a weight-loss
maintenance period.
2. Experimental Section
2.1. Study Design and Participants
The current study was nested within the FP-7 European Com-
mission project Satiety Innovation (SATIN) work package 5, in-
cluding participants from Denmark and Spain.
SATIN was a two-phase, double blinded parallel, random-
ized multicenter study, including women and men aged be-
tween 20 and 65 years with an initial body mass index (BMI)
of 27.0–35.0 kg m−2, fat mass of no less than 23%, and with-
out comorbidities. Participants with significant weight changes
(±3kg in the last 3 months), severe chronic medical condi-
tions (type 1 or 2 diabetes, cardiovascular diseases, hyperten-
sion, chronic kidney diseases, liver diseases, active inflammatory
bowel diseases, cancer, bariatric surgery and other interventions,
psychological or behavioral problems, psychiatric disorders),
drug addictions, regular alcohol consumption above recom-
mendations and smoking (including smoking cessation within
the last three months prior to study) were excluded from the
study.
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The study comprises an initial 8-week low-calorie diet (LCD)
period where participants were instructed to follow the Modifast
(Nutrition et Santé SAS) formula diet to achieve at least an 8%
of weight reduction needed for the inclusion in the randomized
part of the study. Participants reaching the pre-defined weight
loss entered in a 7–10 days run-in period for diet stabilization
and then were randomly allocated in a 1:1 ratio to one of the
two intervention groups; (1) including an active satiety enhanc-
ing product (active intervention group) or (2) including a simi-
lar control product without satiety enhancing properties (control
group) for 12-weeks (weight-loss maintenance period). Detailed
information of the study protocol and procedures has been pub-
lished elsewhere.[14,15]
All procedures were conducted in accordance with the ethical
principles set forth in the current version of the Declaration
of Helsinki (Fortaleza, Brazil, October 2013). The protocol was
approved by the local institutional review boards and Ethics
Committees of all the recruiting centers and all participants
provided written informed consent. This trial was registered in
clinicaltrials.gov (identifier: NCT02485743). Also, all study pro-
cedures were aligned between sites before initiation of the study
and on-site monitoring visits were carried out by an independent
monitor.
Out of 236 participants with blood samples available at base-
line, we have included in this analyses a total of 162 participants
randomized to the weight-lossmaintenance period with available
blood samples (Figure S1, Supporting Information) (75 subjects
from Reus and 87 from Copenhagen). Seven participants were
excluded because lack of adiposity measures after the weight loss
maintenance period (Figure S1, Supporting Information).
2.2. Assessment of Energy Intake and Physical Activity
Nutritional data were collected at baseline, after the 8 weeks of
LCD and at the end of a 12-week weight loss maintenance period
using 3-day dietary records, and energy intakes were calculated
using Danish and Spanish food composition tables.[16]
Participants were asked to wear an ActiGraph tri-axis ac-
celerometer monitor (GT3X+) on the right hip using an elas-
tic belt for 7 consecutive days at baseline, after the 8 weeks of
LCD and at the end of a 12-week weight loss maintenance pe-
riod. They were only allowed to remove the accelerometer during
water activities (i.e., showering or swimming). At the end of the
observation period, data were reintegrated to 60-s epochs and an-
alyzed using ActiLife6 (the ActiGraph 2012, ActiLife version 6).
Before analysis of physical activity, self-reported sleep duration
and non-wear time defined as 60 min of consecutive zeros using
vector magnitude were removed, allowing for 2 min of non-zero
interruptions with amaximum of 100 counts min−1 (CPM). Total
physical activity (CPM) was expressed as vector magnitude of the
total tri-axial counts from monitor wear time divided by monitor
wear time.
2.3. Body Composition and Biochemical Measurements
Anthropometric measures (body weight, height, and sagittal
abdominal diameter) were determined by trained personnel at
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baseline, after the 8 weeks of LCD and at the end of a 12-week
weight loss maintenance period. BMI was calculated. Body
composition was assessed by dual-energy X-ray absorptiometry
(DXA) (Lunar Prodigy Primo, GEHealthcare, Little Chalfont,
UK, in participants from Reus) and GE Lunar iDXA, Encore
software version 16.2 (in participants fromCopenhagen). Fasting
blood samples were obtained at baseline and after the 8-weeks
weight-loss period. Glucose and insulin concentrations were
measured using standard enzymatic automated methods and
the insulin resistance index (HOMA-IR) was estimated.[17] Total
cholesterol, high-density lipoprotein (HDL-C) cholesterol and
low-density lipoprotein (LDL-C) cholesterol levels were mea-
sured using standard enzymatic automated methods (COBAS;
Roche Diagnostics Ltd.).
2.4. Multiplatform Targeted Metabolomics
Metabolites were analyzed at baseline and after the 8 weeks
of LCD using a multiplatform approach including gas
chromatography coupled to high resolution mass spectrometry
(GC-HRMS), liquid chromatography coupled to high resolution
mass spectrometry (LC-HRMS), and proton nuclear magnetic
resonance (1H-NMR). The analytical procedures are specified
in the Supplemental Methods. Information about the mass to
charge ratio, retention time, repeatability and reproducibility
(expressed as RSD) for each metabolite is shown in Table S1,
Supporting Information.
2.5. Statistical Analyses
Baseline results were expressed as mean ± standard deviation
(SD) for continuous variables and percentages for categorical
variables. Eight-weeks and between the end of the 8-week inter-
vention and the conclusion of the 12-week weight-loss mainte-
nance period changes are expressed as mean (95% confidence
interval [CI]). Statistical significance of changes after 8-weeks of
LCD and 12-weeks weight loss maintenance, respectively, was
evaluated using paired t-test. Individual metabolites with equal
or more than 20% missing values were excluded, leaving 123
metabolites for further analyses. Data on metabolites were log-
transformed to improve normality. We first analyzed changes in
metabolites concentrations between baseline and 8-weeks LCD
period using paired t-test. Two-sided p values were reported ac-
cording to an alpha level = 0.0004 (alpha = 0.05 with Bonfer-
roni correction for 123 independent tests [including 123 metabo-
lites]). For those metabolites found to change significantly, we
assessed their associations with improvements in body weight
and adiposity measures (fat mass, sagittal abdominal diameter)
during the 8-week LCD period. With respect to metabolites, we
first calculated the difference between 8-week log-transformed
value and baseline log-transformed value and then scaled these
differences to multiples of 1 SD. Linear regression models were
fitted to examine these associations adjusting for age, sex, BMI
at baseline (except for the outcome body weight change), value
for the respective outcome traits at the baseline examination,
and the respective metabolite at baseline. The Bonferroni cor-
rection for 60 independent tests (including 60 metabolites) for
each respective outcome trait was applied and significance was
reported according to an alpha level = 0.0008 (alpha corrected ac-
cording to the significant changes in Table 1). Metabolites found
significantly associated with body weight and adiposity were as-
signed into specific metabolic pathways based on the pathway
analysis using MetaboAnalyst 5.0. To test whether changes in the
metabolites found to associate significantly with improvements
in adiposity measures were significantly associated with changes
in adiposity measures during the 12-week weight loss mainte-
nance period, linear regression models were fitted for each out-
come trait.Multivariate-adjustedmodels were performed, includ-
ing age, sex, BMI at baseline (except for the outcome body weight
change), value for the respective outcome traits at the baseline
examination, intervention group (enhancing satiety foods, con-
trol foods), and the respective metabolite at baseline. Bonfer-
roni correction for the number of tests based on the number of
metabolites found to associate significantly with adiposity mea-
sures was applied (alpha corrected for weight and total fat in
Table 2). To test the robustness of these associations, we con-
ducted two sensitivity analyses: (1) adding into the multivariable
model 2 covariates such as changes in energy intake and phys-
ical activity during 8 weeks and (2) further adjusting the multi-
variable model for change in the respective outcome traits during
8 weeks instead of their value at the baseline examination. A lo-
gistic regression model was also performed to calculate odds ra-
tios (ORs) and 95% CIs for adiposity regain according to 1 SD
log-transformed changes in the metabolites. For this analysis,
participants were categorized into either the body weight or to-
tal fat regain group or sustained weight loss or total fat reduction
group (reference group). Statistical analyses were performed us-
ing Stata 14.1 (Stata Corp.).
3. Results
3.1. Characteristics of the Study Participants
Descriptive characteristics are shown in Table 3. The mean age
of the study population was 47.3 ± 9.9 years with body weight
of 88.1 ± 10.7 kg and BMI of 30.9 ± 2.0 kg m−2 when initi-
ating the 8-week LCD period. No significant differences in the
general characteristics of the 162 participants included in the
present analyses and those participants initially recruited in the
SATIN study were observed (Table S2, Supporting Information).
The average weight loss for the 162 participants achieving ≥8%
during the LCD was 9.7 kg (p < 0.001). During this period, par-
ticipants also reduced BMI (–3.1 kg m−2) (p < 0.001), total fat
(–7.2 kg) (p < 0.001) and sagittal abdominal diameter (−3.1 cm)
(p < 0.001). Furthermore, total energy intake and physical activ-
ity significantly decreased and increased, respectively. After the
12-week weight loss maintenance period, seven participants did
not have adiposity measures and the 155 remaining regained on
average 1.0 kg (p< 0.001). Of the study participants, 69% showed
weight regain (2.3kg), whereas 31% showed further weight loss
(−1.9 kg). Correspondingly, 61% of the participants regained
(1.6 kg) and 39% lost (–1.9 kg) additional total fat. During this
period, both energy intake and physical activity did not signifi-
cantly change.
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Table 1. Changes in adiposity measures at 8 weeks of a low-calorie diet (LCD) per 1SD log-transformed changes in the concentrations of metabolites.
Change in metabolite between
baseline and 8 weeks LCD
Change in body weight Change in fat mass Change in sagittal
abdominal diameter
Free cholesterol 0.19 (−0.25, 0.64) 0.27 (−0.07, 0.62) 0.005 (−0.21, 0.22)
Esterified cholesterol 0.34 (−0.07, 0.75) 0.32 (−0.010, 0.64) 0.03 (−0.17, 0.24)
Total cholesterol −0.14 (−0.55, 0.27) −0.05 (−0.37, 0.26) 0.04 (−0.15, 0.24)
Triglycerides 0.45 (0.02, 0.89) 0.46 (0.12, 0.80) 0.09 (−0.13, 0.31)
Phosphatidylcholine 0.42 (−0.003, 0.85) 0.29 (−0.04, 0.63) 0.02 (−0.19, 0.24)
Lysophosphatidylcholine 0.59 (0.17, 1.00) 0.36 (0.03, 0.69) 0.08 (−0.13, 0.29)
Sphingomyelin −0.16 (−0.62, 0.30) 0.04 (−0.31, 0.39) −0.21 (−0.43, 0.009)
Fatty acyl chains 0.40 (−0.07, 0.87) 0.49 (0.13, 0.85) 0.06 (−0.17, 0.30)
Monounsaturated fatty acid 0.08 (−0.29, 0.47) 0.09 (−0.21, 0.39) −0.02 (−0.20, 0.16)
LPC 14:0 1.53 (1.09, 1.98)* 0.83 (0.45, 1.20)* 0.38 (0.14, 0.62)
LPC 20:3 1.02 (0.59, 1.45)* 0.52 (0.15, 0.88) 0.26 (0.05, 0.48)
PC 30:0 1.36 (0.89, 1.84)* 0.79 (0.40, 1.17)* 0.19 (−0.07, 0.45)
PC 32:1 0.94 (0.50, 1.37)* 0.66 (0.32, 0.99)* 0.11 (−0.11, 0.33)
PC 32:2 1.39 (0.96, 1.83)* 0.78 (0.41, 1.15)* 0.21 (−0.02, 0.45)
PC 33:1 1.04 (0.58, 1.51)* 0.65 (0.29, 1.01) 0.09 (−0.16, 0.33)
PC 34:4 1.42 (0.96, 1.88)* 0.91 (0.52, 1.29)* 0.25 (0.009, 0.50)
PC 35:1 0.58 (0.09, 1.07) 0.36 (−0.02, 0.74) 0.12 (−0.13, 0.37)
PC 36:1 1.10 (0.65, 1.55)* 0.60 (0.24, 0.96) 0.15 (−0.07, 0.39)
PC 36:4e 0.09 (−0.46, 0.64) 0.03 (−0.40, 0.47) −0.15 (−0.42, 0.11)
PC 36:5 0.36 (−0.04, 0.77) 0.33 (0.01, 0.64) 0.03 (−0.16, 0.23)
PC 38:3 1.26 (0.89, 1.63)* 0.80 (0.49, 1.10)* 0.27 (0.08, 0.46)
PC 38:4 0.42 (−0.09, 0.93) 0.38 (−0.02, 0.78) 0.05 (−0.20, 0.29)
PC 38:4e 0.09 (−0.39, 0.57) 0.04 (−0.34, 0.42) −0.05 (−0.29, 0.18)
PC 40:4 0.76 (0.27, 1.25) 0.36 (−0.02, 0.75) 0.10 (−0.14, 0.34)
PC 40:6 −0.07 (−0.51, 0.35) 0.17 (−0.16, 0.50) 0.03 (−0.17, 0.23)
PE 36:5e 0.42 (−0.02, 0.86) 0.07 (−0.28, 0.43) 0.07 (−0.16, 0.29)
PE 38:5e 0.16 (−0.30, 0.63) −0.19 (−0.56, 0.18) 0.009 (−0.22, 0.24)
PE 38:6e 0.54 (0.03, 1.05) 0.11 (−0.31, 0.52) 0.09 (−0.16, 0.34)
SM 32:1 0.91 (0.47, 1.35)* 0.64 (0.29, 0.99)* 0.07 (−0.15, 0.30)
SM 32:2 1.17 (0.69, 1.66)* 0.77 (0.39, 1.16)* 0.28 (0.04, 0.53)
SM 33:1 −0.24 (−0.72, 0.23) −0.07 (−0.44, 0.29) −0.13 (−0.35, 0.10)
SM 35:1 −0.53 (−0.95, −0.10) −0.13 (−0.46, 0.21) −0.20 (−0.41, 0.01)
SM 36:0 −0.81 (−0.31, −0.32) −0.31 (−0.71, 0.09) −0.19 (−0.47, 0.07)
SM 36:1 −0.59 (−1.02, −0.16) −0.11 (−0.45, 0.23) −0.10 (−0.32, 0.11)
SM 38:1 0.76 (0.35, 1.17)* 0.59 (0.26, 0.91) 0.11 (−0.09, 0.32)
SM 40:1 0.74 (0.28, 1.20) 0.49 (0.12, 0.86) 0.21 (−0.02, 0.43)
SM 40:2 0.42 (−0.05, 0.89) 0.30 (−0.07, 0.67) −0.01 (−0.24, 0.22)
SM 41:1 0.76 (0.27, 1.24) 0.42 (0.03, 0.81) 0.15 (−0.09, 0.39)
SM 41:2 0.20 (−0.42, 0.82) −0.09 (−0.57, 0.39) 0.32 (0.03, 0.61)
SM 42:1 0.67 (0.17, 1.18) 0.38 (−0.02, 0.79) 0.18 (−0.06, 0.43)
TG 50:2 0.41 (−0.03, 0.86) 0.43 (0.08, 0.78) 0.17 (−0.05, 0.39)
Lactic acid 0.42 (−0.01, 0.87) 0.33 (−0.03, 0.68) 0.10 (−0.12, 0.32)
Glycolic acid 0.05 (−0.45, 0.56) −0.41 (−0.78, −0.03) −0.03 (−0.27, 0.21)
Valine 0.46 (0.02, 0.91) 0.10 (−0.25, 0.45) 0.004 (−0.21, 0.22)
Glutamate 0.69 (0.28, 1.10) 0.39 (0.06, 0.72) 0.30 (0.10, 0.50)
Glucose 0.32 (−0.13, 0.78) 0.28 (−0.08, 0.63) 0.03 (−0.19, 0.25)
Tyrosine 0.65 (0.23, 1.08) 0.42 (0.08, 0.76) −0.05 (−0.26, 0.16)
LPC 16:0 0.14 (−0.38, 0.67) 0.02 (−0.38, 0.43) 0.03 (−0.22, 0.29)
LPC 16:1e −0.50 (−0.92, −0.08) −0.34 (−0.67, −0.01) −0.17 (−0.38, 0.04)
(Continued)
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Table 1. Continued.
Change in metabolite between
baseline and 8 weeks LCD
Change in body weight Change in fat mass Change in sagittal
abdominal diameter
LPC 18:1 0.13 (−0.33, 0.59) −0.10 (−0.46, 0.25) −0.04 (−0.27, 0.19)
LPC 18:2 0.26 (−0.16, 0.68) −0.05 (−0.38, 0.28) −0.03 (−0.23, 0.17)
LPC 20:0 0.27 (−0.21, 0.76) 0.001 (−0.39, 0.39) 0.08 (−0.16, 0.32)
LPC 20:1 −0.23 (−0.66, 0.20) −0.17 (−0.50, 0.16) 0.04 (−0.17, 0.26)
LPC 20:4 −0.12 (−0.54, 0.30) −0.04 (−0.37, 0.28) 0.01 (−0.19, 0.22)
LPC 22:6 −0.15 (−0.53, 0.23) −0.05 (−0.35, 0.25) −0.02 (−0.20, 0.17)
PC 34:2e −0.88 (−1.32, −0.44)* −0.89 (−1.22, −0.56)* −0.34 (−0.55, −0.13)
PC 42:5e −0.75 (−1.15, −0.36)* −0.43 (−0.74, −0.11) −0.15 (−0.35, 0.04)
SM 42:3 −1.13 (−1.52, −0.75)* −0.35 (−0.68, −0.02) −0.27 (−0.47, −0.06)
Glycine −0.41 (−0.82, −0.001) −0.29 (−0.61, 0.03) −0.06 (−0.27, 0.14)
Citric acid −1.43 (−0.80, −1.06)* −0.91 (−1.21, −0.61)* −0.45 (−0.65, −0.26)*
Values presented as beta estimates (95% confidence interval) and each regression was adjusted for age, sex, BMI at baseline (except for the outcome body weight change),
value for the respective outcome traits at the baseline examination, and the respective metabolite at baseline. BMI, body mass index; LPC, lysophosphatidylcholine; PC,
phosphatidylcholine; PE, phosphatidylethanolamine; SD, standard deviation; SM, sphingomyelin; TG, triglyceride. *Significant after Bonferroni correction for 60 tests.
Table 2.Changes in adipositymeasures after the 12-weekweight lossmain-
tenance period per 1SD log-transformed changes in the concentrations of
metabolites during the initial 8 weeks.
Change in metabolite between
baseline and 8 weeks
Change in body weight Change in fat mass
LPC 14:0 0.90 (0.34, 1.46)* 1.11 (0.61, 1.62)*
LPC 20:3 0.84 (0.36, 1.32)* NA
PC 30:0 0.35 (-0.24, 0.94) 0.64 (0.10, 1.18)
PC 32:1 0.25 (-0.25, 0.75) 0.37 (-0.09, 0.83)
PC 32:2 0.76 (0.24, 1.28) 1.03 (0.54, 1.51)*
PC 33:1 0.17 (-0.37, 0.71) NA
PC 34:4 0.78 (0.23, 1.33) 1.08 (0.57, 1.59)*
PC 36:1 0.53 (0.01, 1.05) NA
PC 38:3 0.82 (0.40, 1.24)* 1.09 (0.70, 1.47)*
SM 32:1 0.19 (-0.31, 0.70) 0.31 (-0.17, 0.79)
SM 32:2 0.76 (0.21, 1.32) 0.94 (0.42, 1.46)*
SM 38:1 0.63 (0.19, 1.07) NA
PC 34:2e -0.59 (-1.09, -0.11) -0.65 (-1.11, -0.19)
PC 42:5e -0.18 (-0.63, 0.26) NA
SM 42:3 -0.54 (-1.00, -0.08) NA
Citric acid -0.48 (-0.95, -0.02) -0.81 (-1.21, -0.40)*
Values presented as beta estimates (95% confidence interval) and each regression
was adjusted for age, sex, BMI at baseline (except for the outcome body weight
change), value for the respective outcome traits at the baseline examination, inter-
vention group (satiety controlling foods, control foods), and the respective metabo-
lite at baseline. NA indicates no analysis performed for the metabolite and adiposity
measure because in Table 2 these parameters were not significantly associated. BMI,
body mass index; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; SD, stan-
dard deviation; SM, sphingomyelin. *Significant after Bonferroni correction for 15
and 10 tests for the outcomes weight and total fat, respectively
3.2. Association Between Changes in Metabolite Levels and
Changes in Adiposity Measures During the 8-week LCD
After correction for multiple testing, 60 metabolites showed
a significant change from baseline to the end of the 8 weeks
LCD period (Table S3, Supporting Information). Changes in
metabolite concentrations associated with changes in adiposity
measures are shown in Table 1. Weight loss-induced decrease in
lysophosphatidylcholines (LPCs) 14:0, LPC 20:3, phosphatidyl-
cholines (PCs) 30:0, PC 32:1, PC 32:2, PC 33:1, PC 34:4, PC 36:1,
PC 38:3, sphingomyelins (SMs) 32:1, SM 32:2, SM 38:1, and
increase in PC 34:2e, PC 42:5e, SM 42:3 and citric acid (Table S3,
Supporting Information) were associated with a decreased body
weight (Table 1). A decrease in the concentrations of LPC 14:0,
PC 30:0, PC 32:1, PC 32:2, PC 34:4, PC 38:3, SM 32:1, SM 32:2,
and an increase in the concentrations of PC 34:2e and citric acid
(Table S3, Supporting Information) were also associated with a
decrease in total fat (Table 1). Finally, an increase in citric acid
concentrations was found to be associated with a decrease in
sagittal abdominal diameter. Similar results were found after
adjusting analyses for changes in energy intake and physical
activity except for the association of SM 38:1 and PC 42:5e with
body weight, of PC 32:1, PC 32:2 and SM 32:2 with total fat,
and of citric acid with abdominal measure (Table S4, Supporting
Information). Eight distinct metabolic pathways were identified,
mapping to the metabolite set significantly associated with body
weight and total fat changes (Figure 1). The metabolic pathway
with the highest impact (based on p values derived from pathway
analyses) was related to glycerophospholipid metabolism, while
amoderate impact was found for linoleic acidmetabolism, alpha-
linolenic acid metabolism, citric acid cycle, and sphingolipid
metabolism.
3.3. Association Between Changes in Metabolite Levels During
8-Weeks LCD and Changes in Adiposity Measures During the
12-Week Weight-Loss Maintenance Period
We then investigated whether the initial (8 weeks) changes in
these metabolites were significantly associated with changes in
adiposity measures during the 12-week weight-loss maintenance
period. We observed that decreases in LPC 14:0, LPC 20:3, and
PC 38:3 were associated with body weight regain (Table 2). Also,
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Table 3. General characteristics of the study subjects at baseline, after the 8-week LCD and after the 12-week weight loss maintenance period.
Baseline (n = 162) 8 weeks change (n = 162) Weight loss maintenance
change (n = 155)
p value for 8 weeks
change
p value for weight loss
maintenance change
Sex (%Women) 75.0 NA NA NA NA
Age [yrs] 47.5 ± 9.9 NA NA NA NA
Height [m] 1.68 ± 0.09 NA NA NA NA
Weight [kg] 88.1 ± 10.7 −9.7 (−10.2, −9.2) 1.0 (0.6, 1.4) <0.001 <0.001
BMI [kg m−2] 30.9 ± 2.0 −3.4 (−3.5, −3.2) 0.3 (0.2, 0.5) <0.001 <0.001
Total fat [kg] 36.1 ± 5.6 −7.2 (−7.5, −6.9) 0.003 (−0.3, 0.4) <0.001 0.984
Bone mass [kg] 2.8 ± 0.5 −0.01 (−0.02, −0.0005) −0.009 (−0.02, 0.0006) 0.040 0.065
Sagittal diameter [cm] 23.2 ± 2.4 −3.1 (−3.3, −2.8) 0.6 (0.4, 0.8) <0.001 <0.001
Glucose [mg dL−1] 94.9 ± 11.2 −2.9 (−4.1, −1.8) −0.5 (−1.5, 0.6) <0.001 0.367
Insulin [mcUI mL−1] 9.1 ± 6.4 −3.2 (−3.9, −2.5) 0.2 (−0.2, 0.7) <0.001 0.361
HOMA−IR 2.2 ± 1.7 −0.8 (−1.0, −0.6) 0.04 (−0.07, 0.1) <0.001 0.482
TChol [mg dL−1] 197.6 ± 34.9 −19 (−23.4, 16.2) 15.1 (11.6, 18.6) <0.001 <0.001
HDL−C [mg dL−1] 56.3 ± 15.9 −5.2 (−6.5, −3.8) 10.3 (8.9, 11.7) <0.001 <0.001
LDL-C [mg dL−1] 120.6 ± 30.9 −12.3 (−15.5, −9.2) 5.9 (2.9, 8.9) <0.001 <0.001
EI [kcal d−1] 1953.5 ± 633.5 −400.8 (−502.3, −299.2) 57.5 (−26.7, 141.8) <0.001 0.179
TPA (CPM) 608.9 ± 187.9 47.9 (23.5, 72.4) −14.9 (−46.4, 16.5) <0.001 0.348
Baseline data are presented as mean ± standard deviation unless otherwise indicated. Data are presented as mean (95% confidence interval) for changes after 8 weeks of
LCD and changes between the end of the 8-week intervention and the conclusion of the 12 week weight maintenance period. The paired t test was used to assess changes
in variables between baseline and 8 weeks of LCD and after the 12 weeks of weight loss maintenance period. BMI, body mass index; CPM, counts min−1; EI, energy intake;
HDL-C, high-density lipoprotein-cholesterol; LCD, low-calorie diet; LDL-C, low-density lipoprotein-cholesterol; TChol, total cholesterol; TPA, total physical activity.
Figure 1. Metabolic pathway analysis.
initial decreases in LPC 14:0, PC 32:2, PC 34:4, PC 38:3, SM
32:2 were associated with total fat increase, whereas increases
in citric acid was associated with total fat decreases (Table 2).
In sensitivity analyses, the associations between decreases in
these metabolites and total fat regain persisted after adjustment
for changes in total fat (Table S5, Supporting Information). On
the other hand, only decreases in PC 38:3 remained signifi-
cantly associated with body weight regain after adjustment for
weight changes (Table S5, Supporting Information). Finally, we
investigated whether the initial changes in metabolites were
associated with failure to maintain weight loss and total fat loss
during the weight loss maintenance period. We found that the
initial decreases in PC 32:2 and PC 38:3 concentrations were
associated with an increased risk of body weight regain (OR 2.66;
95% CI 1.41, 5.02 and OR 2.18; 95% CI 1.39, 3.41, respectively)
(Figure 2A). We also observed that initial decreases in LPC 14:0,
PC 32:2, PC 34:4, and PC 38:3 were associated with increased
risk of total fat regain (OR 4.60; 95% CI 2.27, 9.33, OR 4.51; 95%
CI 2.22, 9.16, OR 5.48; 95% CI 2.42, 12.39, and OR 2.81; 95% CI
1.74,4.54, respectively) (Figure 2B). Conversely, initial increases
in the concentrations of PC 34:2e and citric acid were associated
with decreased risk of total fat regain (OR 0.47; 95% CI 0.29,
0.76 and OR 0.32; 95% CI 0.19, 0.53, respectively) (Figure 2B).
On the other hand, no significant associations between 8 weeks
changes in citric acid and changes in sagittal abdominal diam-
eter during the 12-week weight loss maintenance period were
observed.
4. Discussion
In the present study, we found that changes in several metabo-
lites involved in different metabolic pathways, including glyc-
erophospholipid, linoleic acid/alpha-linolenic acid and sphin-
golipid metabolism, and citric acid cycle, during an 8-week LCD
were associated with a reduction in body weight and total fat. Fur-
ther, our results indicated that changes in certain lipid species
and citric acid during weight loss were related to weight and adi-
posity regain after 12 weeks of weight loss maintenance.
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Figure 2. Probability of weight gain at 12-weeks according to 1SD log-transformed changes in the concentrations of metabolites during the initial 8 weeks
low calorie diet. Figure 2B. Probability of total fat increase at 12-weeks according to 1SD log-transformed changes in the concentrations of metabolites
during the initial 8 weeks low calorie diet. Odds ratios with 95% confidence interval (log scale) after adjustment for age, sex, BMI at baseline (except for the
outcome body weight change), value for the respective outcome traits at the baseline examination, intervention group (satiety controlling foods, control
foods), and the respective metabolite at baseline. *Significant after Bonferroni correction for 15, 10 tests for the outcomes body weight and total fat,
respectively. Abbreviations: BMI; body mass index, LPC; lysophosphatidylcholine, PC; phosphatidylcholine, SD, standard deviation; SM; sphingomyelin.
According to previous studies, obesity results in generally
higher lipid load in circulation characterized by increased con-
tent of cholesterol fatty acid, PC, PE, and LPC species.[18,19] After
8 weeks of an LCD, we observed reductions in the concentrations
of cholesterol and lipid species (mainly PCs and SMs, two LPCs),
in line with the findings of a previous study,[10] whereas eight
LPC species increased. Contradictive findings related to alter-
ations of LPC in obesity have been reported. Some studies
showed decreased levels of these compounds,[20–22] while other
studies have demonstrated increases with obesity.[17] Schwab
et al.[23] could not observe significant alterations in circulating
LPC levels after a 33-week period of weight loss in nine obese
subjects. On the contrary, we found a significant relationship
of decreases in the concentrations of LPC 14:0 and LPC 20:3
with reduction in adiposity. We also observed that decreases in
five PCs (PC 30:0, PC 32:1, PC 32:2, PC 34:4, PC 38:3) and
three SMs (SM 32:1, SM 32:2, SM 38:1) were consistently asso-
ciated with reductions in body weight and total fat at 8 weeks,
linking their modulation with adiposity improvement.[22,23] On
the other hand, increases in two PCs (PC 34:2e, PC 42:5e) and
SM 42:3 were associated with adiposity reduction. These find-
ings imply that the observed changes were entirely dependent
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upon changes in adiposity, unlike the other metabolites (NMR
lipids, phosphatidylethanolamine species, organic acids, amino
acids) that may be influenced by different mechanisms. Previous
studies revealed decreased adipose lipid turnover and lipolytic
activity in subjects with overweight and obesity,[24] while substan-
tial weight loss and adiposity reduction is explained by increased
lipid removal and decreased lipid storage. Changes in the concen-
trations of circulating phospholipids and SMs during weight loss
may reflect altered synthesis and efflux from adipose tissue.[25]
Besides this, our findings in relation to decreases in lipid species
including glycerophospholipids and sphingolipids may also be
explained via the lipotoxicity hypothesis. This hypothesis states
that an oversupply of dietary fats, which exceed the capacity of
adipocytes to store them, leads to storage in other tissues, such as
hepatocytes.[26] A reduction in adiposity during the 8-week LCD
may have resulted to their reduced storage in the liver and ex-
cretion into the bloodstream.[22] Since elevated PC (<5 double
bonds) and SM levels have been found to be associated with in-
creased risk of coronary artery disease andmortality,[27,28] it could
be speculated that the decreases in PC and SM could be involved
in the beneficial health effects of weight loss.[29]
Our study also showed that decreases in the concentrations of
PC 38:3 during the LCD were related to weight regain and in-
creases in total fat during the 12-week weight loss maintenance
period. Similar results were obtained for decreases in PC 32:2
and weight/total fat increases as well as for decreases in PC 34:4
and total fat increases. Conversely, early increases in PC 34:2e
were associated with further fat loss. Early decreases in LPC 14:0
and LPC 20:3 were also associated with adiposity gain after the
weight loss maintenance period. Similarly, initial decreases in
plasma SM 32:2 concentrations were also associated with total
fat increases after 12 weeks. In the DiOGenes intervention study,
participants with morbid obesity and high circulating PC and
SM levels were most successful in losing weight upon an 8-week
LCD period,[10] while these compounds decreased. The authors
suggested that these observations might be due to a higher lipid
turnover during the weight loss period which corresponds to a
higher energy metabolism at baseline.[10] Recently, a prospective
study revealed that individuals with a low baseline lipid removal
rate weremore likely to remain weight-stable after weight loss.[30]
On the contrary, our results suggest that an initial increase in
lipid metabolism induced by weight loss was associated with adi-
posity regain identifying the adipose-related alterations in lipid
metabolism with decreased adiposity as an important factor for
the maintenance of lost weight and adiposity.
Our findings are not in agreement with those from previous
studies showing associations of changes in amino acids with
weight loss.[12,31] These studies,[12,31] used long-term weight-loss
diet interventions, whereas our participants followed a shorter
LCD. In a previous study, weight loss by short-term LCD inter-
vention did not lower circulating amino acids.[32] However, differ-
ences in study design can only partly explain these discrepancies.
Citric acid, an intermediate of the citric acid cycle, was found
to increase after the first 8 weeks and was associated with weight
loss and decreases in all adiposity measures during this period.
Increases in citric acid have been noted in plasma of adults with
overweight and obesity after a 12-week LCD and subsequent
weight loss ≥7.2 kg.[8] The plasma citric acid homeostasis is
mainly regulated and maintained by the bone and about 90% of
the total plasma citric acid in the body resides in bone.[33] During
weight loss, changes in bone metabolism may occur. We found a
significant reduction in total bone mass after 8 weeks. Previous
diet-induced weight loss interventions of longer duration (rang-
ing from 6 months to 1 year) have indicated that a weight loss of
≈10% (similar to our study) results in a 1–2% bone loss at the
hip and total body.[34,35] According to a meta-analysis, interven-
tions of 2 or 3 months in duration induced significant increases
in serum concentrations of osteocalcin, indicating an early ef-
fect of such weight loss programs to promote a bone catabolic
state.[36] Therefore, we speculate that weight loss might have in-
duced bone breakdown releasing citric acid from bone to plasma
contributing to the increases in plasma citric acid concentrations
observed in our study after the LCD.[33] Interestingly, our results
indicated that initial (8-weeks) increases in citric acid concentra-
tions were associated with total fat reduction and total fat reduc-
tion during the weight loss maintenance period. Whether such
a metabolite could be used as marker of total fat reduction and
whether bone metabolism changes might have persisted during
the weight loss maintenance period are hypotheses that require
further investigation.
Our study has several strengths. A comprehensive metabo-
lite profiling was performed using combinations of different
metabolomic platforms to quantitatively analyze a wide range of
metabolites. Our study participants were free of type 2 diabetes
or cardiovascular diseases and were non-smokers, all factors that
may affect the concentrations of these metabolites. The consis-
tent findings of themetabolites and adipositymeasurements dur-
ing the LCD period strengthen our conclusion.
Concerning limitations, participants were overweight/obesity
without comorbidities and this may limit the generalizability of
the findings to overweight/obese individuals with obesity-related
comorbidities. Furthermore, although we adjusted for several po-
tential confounders, residual confounding cannot be ruled out.
An additional limitation could be that the SATIN sample lacked
a control group to rule out that the observed changes in plasma
metabolite concentrations may be related to the time course
rather than to the change in body weight or adiposity. Finally,
the use of a targeted metabolomic approach only, may have lim-
ited the discovery of newmetabolites associated with body weight
or fat mass changes. Untargeted metabolomics could comple-
ment our approach providing a more comprehensive view of the
metabolic changes that accompany weight loss and could be as-
sociated with weight and adiposity regain.
In conclusion, changes in circulating concentrations of sev-
eral lipid species including PCs, LPCs, and SMs were associ-
ated with greater improvement of body weight and adiposity
in adults with overweight/obesity following a LCD. These data
are intriguing in light of a growing body of literature suggest-
ing that weight loss and adiposity reductions are associated with
changes in lipid metabolism. Decreases in the concentrations of
LPC 14:0, LPC 20:3, PC 32:2, PC 38:3, SM 32:2, and increases
in citric acid concentrations during weight loss, which were re-
lated to adiposity regain and loss, respectively, could help us to
understand the potential role of metabolic responses for the abil-
ity to resist weight-loss regain. Further studies are warranted to
replicate these results in other populations and try to establish
metabolites as potential biomarkers for successful weight loss
maintenance.
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